My dad was diagnosed with stage IV NSCLC with bone metastasis about Sept 2013.
He started taking Irressa in Nov 2013.
In Feb 2015, he started progressing on Iressa and entered the AZD9291 trial.
Currently, the 2nd EGFR inhibitor AZD9291 is working and he is stable.
Eventually, however, he will progress on AZD9291 and we will have to explore options.
From my research, the leading immunotherpy drugs in clinical trial are two below.
Nivolumab CheckMate 012
1.Those are the two available in Toronto, is there any other promising drugs in US?
I believe Nivolumab and MEDI4736 are both anti PD-L1, is there any other types?
2.When is the good time to explore immunotherpy?
The standard care after progression on AZD9291 is chemo with either cis or carbo.
Should we explore immunotherpy before or after chemo.
3.Is there any other alternatives besides chemo?
Maybe a another EGFR inhibitor?(just a wild guess)